Study
Whole genome, exome and transcriptome analysis to guide individualized cancer interpretation
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001004013 | Other |
Study Description
Study Design: The Cancer Alliance study was a collaboration of nine academic medical institutions in the New York city area and led by the New York Genome Center. Tumor-normal paired samples were submitted by the institutions for whole genome, whole exome and transcriptome sequencing and bioinformatics analysis at New York Genome Center. Relevant clinical histories were also collected. Raw sequence files were available to all collaborators. Variant call files were analyzed both manually by interpreters at NYGC and by IBM Watson Genome Analytics. This study was approved by a central institutional review board (IRB), Biomedical Research Alliance of New York, and by local IRBs, including Stony Brook University and Northwell Health. The study was supported in part by a grant from the IBM corporation (IBM Watson Health) to the New York Genome Center, New York Genome Center philanthropic funds and Rockefeller University grant # UL1TR000043 from the National Center for Advancing Translational Sciences (NCATS), and the National Institutes of Health (NIH) Clinical and Translational ... (Show More)
Study Datasets 4 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001006233 |
Whole genome sequencing for individualized cancer interpretation
|
94 | |
| EGAD00001006234 |
PolyA selection transcriptome profiling by high-throughput for individualized cancer interpretation
|
22 | |
| EGAD00001006235 |
Total RNA transcriptome profiling by high-throughput for individualized cancer interpretation
|
19 | |
| EGAD00001006236 |
Exome sequencing for individualized cancer interpretation
|
90 |
Who archives the data?
